




Interferon beta-1b
 (Extavia®)

Patient Information

Updated: 10.2019

<p>USED FOR</p>	<ul style="list-style-type: none"> Relapsing-remitting forms of multiple sclerosis (MS) Interferon beta-1b will not cure MS. It may prevent and reduce the number of flare-ups and slow disease progression.
<p>HOW IT WORKS</p>	<ul style="list-style-type: none"> Interferon beta-1b is made from human proteins called interferons thought to modify the immune processes responsible for injury to the nervous system from MS.
<p>HOW IT IS SUPPLIED</p>	<ul style="list-style-type: none"> Extavia is therapeutically equivalent to Betaseron and also comes as a single use powder vial (0.3mg) with a single-dose prefilled syringe, but with a vial adapter. Extavia pre-filled syringe (requires mixing of the powder vial with pre-filled syringe contents containing Sodium Chloride, 0.54% solution). <div style="text-align: center;">  </div> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>- Vial adapter:</p>  </div> <div style="text-align: center;"> <p>- Extavia Powder Vial:</p>  </div> </div> <ul style="list-style-type: none"> Extavia Autoinjector II (requires inserting of an already mixed syringe into the device). <div style="text-align: center;">  </div>
<p>DOSE</p>	<ul style="list-style-type: none"> 0.25mg is injected under the skin (subcutaneously) every other day (every 48 hours). If you miss a dose do not inject 2 doses in a row. When first starting, a smaller dose is used, then gradually increased over 6 weeks according to a titration schedule. On the 7th week, use the full 0.25mg dose. You may not need this titration if you are switching from Betaseron. Consider hydrating well and pre-medicating with Acetaminophen (Tylenol) or Ibuprofen (Advil) to prevent flu-like symptoms.

TITRATION SCHEDULE	<table border="1" data-bbox="529 220 1414 436"> <thead> <tr> <th></th> <th>Extavia dose</th> <th>% of full dose</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>Weeks 1-2</td> <td>0.0625 mg</td> <td>25%</td> <td>0.25 mL</td> </tr> <tr> <td>Weeks 3-4</td> <td>0.125 mg</td> <td>50%</td> <td>0.5 mL</td> </tr> <tr> <td>Weeks 5-6</td> <td>0.1875 mg</td> <td>75%</td> <td>0.75 mL</td> </tr> <tr> <td>Week 7 and</td> <td>0.25 mg</td> <td>100%</td> <td>1 mL</td> </tr> </tbody> </table>		Extavia dose	% of full dose	Volume	Weeks 1-2	0.0625 mg	25%	0.25 mL	Weeks 3-4	0.125 mg	50%	0.5 mL	Weeks 5-6	0.1875 mg	75%	0.75 mL	Week 7 and	0.25 mg	100%	1 mL
	Extavia dose	% of full dose	Volume																		
Weeks 1-2	0.0625 mg	25%	0.25 mL																		
Weeks 3-4	0.125 mg	50%	0.5 mL																		
Weeks 5-6	0.1875 mg	75%	0.75 mL																		
Week 7 and	0.25 mg	100%	1 mL																		
HOW IT IS GIVEN	<ul data-bbox="451 541 990 913" style="list-style-type: none"> • Interferon beta-1b is injected into fatty area just under the skin in the areas shown to the right. • Do not inject into an area of the where the skin is irritated, reddened, bruised, infected or scarred in any way. • Rotate injection sites to avoid skin reactions. <div data-bbox="1047 489 1474 1052">  </div>																				
STORAGE AND HANDLING	<ul data-bbox="451 1075 1250 1333" style="list-style-type: none"> • When not used, store the powder vials at <i>room temperature</i> 20°C to 25°C (68°F to 77°F). Higher temperatures of 15°C to 30°C (59°F to 86°F) are permitted for up to <i>3 months</i>. • After mixing of the powder, if not used immediately, refrigerate the syringe solution and use <i>within 3 hours</i>. • Safely dispose of used syringes in a sharps container. <div data-bbox="1291 1081 1481 1333">  </div>																				
DRUG INTERACTIONS	<ul data-bbox="451 1369 1291 1402" style="list-style-type: none"> • There are no known drug interactions with Interferon beta-1b. 																				
COMMON SIDE EFFECTS	<ul data-bbox="451 1432 1258 1753" style="list-style-type: none"> • Flu- like symptoms: muscle aches, fever, tiredness, chills. • You may be able to manage with over-the counter (OTC) pain and fever reducers (Acetaminophen or Ibuprofen). For many people, these symptoms lessen or go away over time. • Thyroid problems. • Change in liver function tests. • Injection site problems: redness, pain, swelling. <div data-bbox="1291 1486 1481 1701">  </div>																				

RARE, BUT SERIOUS SIDE EFFECTS	<ul style="list-style-type: none"> • Tell your MS doctor right away if you have any of the following: <ul style="list-style-type: none"> • Depression and suicidal thoughts: feeling hopeless or feeling bad about yourself, and having thoughts of hurting yourself • Liver injury: symptoms may include nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye (jaundice), bleeding more easily than normal, confusion, sleepiness • Serious allergic and skin reactions: itching, swelling of your face, eyes, lips, tongue or throat, trouble breathing anxiousness, feeling faint, skin rash, hives, sores in your mouth or skin blisters and peels. • Skin necrosis at the injection site: any break in the skin, color changes (blue or black), swelling, drainage of fluid from the injection site • Blood problems: low red and white blood cell, and platelet counts that can lead to infections and problems with bleeding and bruising.
MONITORING	<ul style="list-style-type: none"> • You should always check your skin for changes at the injection site. • During your treatment, you will need to have regular blood work to check for side effects. • BEFORE starting Interferon beta-1b, you will need a complete blood count and liver function tests. • AFTER starting Interferon beta-1b, you will need to repeat the blood work at 1 month, 3 months, and 6 months, then every 6 months thereafter.
MORE INFORMATION	<ul style="list-style-type: none"> • Websites: www.extavia.com, www.nationalmssociety.org • Clinical Trials: <ul style="list-style-type: none"> • The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Neurology</i>. 1993;43:665-661.